Get the Stockscreener App
1.675
10.19%
-0.19
After Hours:
1.69
0.015
+0.90%
Agenus Inc stock is traded at $1.675, with a volume of 576.52K.
It is down -10.19% in the last 24 hours and down -52.14% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$1.865
Open:
$1.86
24h Volume:
576.52K
Relative Volume:
1.40
Market Cap:
$39.55M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0244
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-28.72%
1M Performance:
-52.14%
6M Performance:
-73.24%
1Y Performance:
-87.28%
1-Day Range:
$1.67
$1.94
1-Week Range:
$1.67
$2.42
52-Week Range:
$1.67
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
1.675 | 39.55M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL
Agenus stock hits 52-week low at $1.91 amid market challenges - Investing.com Australia
Agenus Inc. Earnings Call: Mixed Sentiments and Strategic Focus - TipRanks
Agenus stock hits 52-week low at $1.91 amid market challenges By Investing.com - Investing.com South Africa
Agenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Call Transcript - MSN
Agenus’ Strategic Cost Reductions and CRC Focus Lead to Hold Rating - TipRanks
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Mo - GuruFocus.com
Agenus Inc. Reports Strategic Cost Reductions and BOT/BAL Progress - TipRanks
Agenus: Q4 Earnings Snapshot - mySA
Agenus stock falls as Q4 revenue drops sharply By Investing.com - Investing.com South Africa
Earnings call transcript: Agenus sees stock jump in Q4 2024 - Investing.com India
Earnings call transcript: Agenus sees stock jump in Q4 2024 By Investing.com - Investing.com UK
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus: Q4 Earnings Snapshot -March 11, 2025 at 07:44 am EDT - Marketscreener.com
Agenus to lower annual burn to about $50 mln by mid-2025 -March 11, 2025 at 07:40 am EDT - Marketscreener.com
Agenus Slashes Cash Burn by 50% While Advancing Promising Cancer Drug Program - StockTitan
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program - Bluefield Daily Telegraph
Earnings Scheduled For March 11, 2025 - Benzinga
Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Contrasting Agenus (NASDAQ:AGEN) and Cortexyme (NASDAQ:CRTX) - Defense World
Agenus (AGEN) Projected to Post Earnings on Tuesday - Defense World
Agenus Inc. to Host Earnings Call - ACCESS Newswire
Agenus stock touches 52-week low at $2.48 amid market challenges - Investing.com Australia
Agenus stock touches 52-week low at $2.48 amid market challenges By Investing.com - Investing.com South Africa
Agenus reports promising sarcoma study results - MSN
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineAGEN - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders That Lost Money on Agenus Inc. (AGEN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Investors who lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class ActionAGEN - ACCESS Newswire
Agenus, Inc. to Host Earnings Call - ACCESS Newswire
Agenus Inc. revises financial agreements, extends warrant terms - Investing.com India
Agenus Inc. revises financial agreements, extends warrant terms By Investing.com - Investing.com South Africa
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - ACCESS Newswire
Levi & Korsinsky Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - ACCESS Newswire
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications - Business Wire
Can Agenus' Cancer Therapy Breakthrough Transform "Cold Tumor" Treatment? - StockTitan
Can Agenus Breakthrough in Colorectal Cancer? CCO to Reveal Strategy at Major Oncology Conference - StockTitan
When Will Agenus Reveal Its 2024 Performance? Key Date for Biotech Investors - StockTitan
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - Business Wire
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Can This Novel Triple Immunotherapy Crack the Code for Treatment-Resistant Gastric Cancer? - StockTitan
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Business Wire
Lost Money on Agenus Inc.(AGEN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):